<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172379</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-E044-204</org_study_id>
    <nct_id>NCT01172379</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With &quot;Wearing Off&quot; Motor Fluctuations and &quot;On&quot; Period Dyskinesias</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With &quot;Wearing Off&quot; Motor Fluctuations and &quot;On&quot; Period Dyskinesias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability and efficacy of E2007 in
      Parkinson's Disease patients who have &quot;wearing off&quot; motor fluctuations and &quot;on&quot; period
      dyskenisias.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, double-blind, placebo-controlled, dose-ranging multicentre study with
      parallel groups. Patients will be equally randomized to receive 0.5 mg, 1 mg or 2 mg of E2007
      or matching placebo for 12 weeks (84 days) in addition to their stable antiparkinsonian
      treatment. The study will involve two overnight in-patient stays. The first of these will be
      for 2 nights and 3 days and the second will be for 1 night and 2 days. The remainder of the
      study will be conducted on an outpatient basis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy assessments: Parkinsonian symptomology will be recorded on an out-patient basis using patient diary cards (indicating &quot;on&quot; and &quot;off&quot; periods, sleep and dyskinesias).</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment>2</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Experimental 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2007</intervention_name>
    <description>Experimental 1 Drug: E2007
0.5 mg 1 tablet per day</description>
    <arm_group_label>Experimental 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2007</intervention_name>
    <description>Experimental 2 Drug: E2007
1.0 mg 1 tablet per day</description>
    <arm_group_label>Experimental 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2007</intervention_name>
    <description>Drug: E2007
2.0 mg 1 tablet per day</description>
    <arm_group_label>Experimental 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Placebo 1 tablet per day</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients with idiopathic PD fulfilling the Queen Square Brain Bank
             diagnostic criteria, with good response to levodopa.

          2. Patients must be aged 30-75 inclusive. Patients aged between 76-80 (inclusive) may be
             enrolled with the prior agreement of the Study Medical Monitor.

          3. Patients must have motor fluctuations of the wearing &quot;off&quot; type with the presence of
             at least two and half hours of &quot;off&quot; time during the waking day and at least 90
             minutes of &quot;off&quot; time during the eight hour period following the morning dose of
             levodopa each per day as evidenced by history at Screening and confirmed by diary data
             collected between Screening and Baseline.

          4. Patients must have clinically relevant dyskinesias during the &quot;on&quot; period following
             each morning dose of his/her current medication.

          5. Patients must rate between II-IV on the Hoehn and Yahr scale when in an &quot;off&quot; state.

          6. Patients must be taking levodopa at least three times daily.

          7. Patients must have been on a fixed dose of any treatments for PD for at least 4 weeks
             prior to the Baseline Visit.

          8. In the Investigator's opinion patients must be able to distinguish their own motor
             states and the absence or presence of dyskinesias.

          9. Patients must be capable of giving full written informed consent.

         10. In the Investigator's opinion patients must be of capable of completing patient diary
             cards according to instructions.

         11. In the Investigator's opinion patients who are good candidates and able to complete
             the study.

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Women of child-bearing potential unless infertile (including surgically sterile) or
             practicing effective contraception (e.g., abstinence, IUD or barrier method plus
             hormonal method). These patients must have a negative serum B-HCG test at the Initial
             Screening Visit and a negative urine pregnancy test at the Baseline Visit. These
             patients must also be willing to remain on their current form of contraception for the
             duration of the study. Postmenopausal women may be recruited but must be amenorrhoeic
             for at least 1 year to be considered of non-child bearing potential.

          3. Fertile men not willing to use reliable contraception and fertile men with partners
             not willing to use reliable contraception.

          4. Patients with a past or present history of drug or alcohol abuse.

          5. Patients with a past (within one year) or present history of psychotic symptoms
             requiring antipsychotic treatment. Patients may be taking anti-depressant medication,
             however, the dose must be stable for 8 weeks prior to the Baseline Visit.

          6. Patients with unstable abnormalities of the hepatic, renal, cardiovascular,
             respiratory, gastrointestinal, haematological, endocrine or metabolic systems which
             might complicate assessment of the tolerability of the study medication.

          7. Patients with significantly elevated liver enzymes (abnormal bilirubin or seum
             transaminase levels of more than 1.5 times the upper normal limit).

          8. Patients currently receiving treatment with medication that could significantly
             interfere with gastric absorption.

          9. Patients with current or prior treatment (within 4 weeks prior to the Baseline Visit)
             with medication known to induce the enzyme cytochrome P450 3A4 including but not
             limited to: carbamazepine; dexamethasone; ethosuximide; phenobarbital; phenytoin;
             primidone; rifabutin; rifampacin; and St. John's Wort.

         10. Current or prior treatment (within 4 weeks prior to Baseline Visit) with methyldopa,
             budipine, reserpine or intermittent use of liquid forms of levodopa or apomorphine.

         11. Patients with previous stereotactic surgery (e.g., pallidotomy) for Parkinson's
             disease.

         12. Patients receiving deep brain stimulation.

         13. Patients who have received an investigational product within 12 weeks prior to
             Baseline Visit or patients that have participated in a previous study with E2007.

         14. Patients with clinically significant cognitive impairment (MMSE ; 24 and/or fulfilling
             DSM IV criteria for dementia due to Parkinson's disease).

         15. Patients with conditions affecting the peripheral or central sensory system unless
             related to Parkinson's disease (mild sensory or pain syndromes limited to off periods)
             that could interfere with the evaluation of any such symptoms caused by the study
             drug.

         16. Patients with any condition that would make the patient, in the opinion of the
             Investigator, unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Webster</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic of Neurology, Faculty Hospital Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Neurology Practise</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Regional Hospital Pardubice</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Faculty of Medicine Charles University</name>
      <address>
        <city>Prague</city>
        <zip>120 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology - Second Faculty of Medicine Charles University</name>
      <address>
        <city>Prague</city>
        <zip>84 - 150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre D'Investigation Clinique Pavillon Riser - Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Competence Network Germany Dept. of Neurology - Philipps-University Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hesse</state>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humboldt Universit?t Charite Neurologische Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Friedrich-Wilhelms- Univerit?t Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>D-53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralkrankenhaus Reinkenheide Neurologische Klinik</name>
      <address>
        <city>Bremerhaven</city>
        <zip>D-27574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Heinrich-Heine- Universit?t</name>
      <address>
        <city>D?sseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis</name>
      <address>
        <city>Erbach</city>
        <zip>D-64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Georg-August- Universit?t</name>
      <address>
        <city>G?ttingen</city>
        <zip>D-37099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit?tskrankenh aus Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Hanau</name>
      <address>
        <city>Hanau</city>
        <zip>D-63450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit?tsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit?tsklinikum</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>D-66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus-Elena-Kli nik</name>
      <address>
        <city>Kassel</city>
        <zip>D-34126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit?tsklinikum Rostock Klinik f?r Neurologie</name>
      <address>
        <city>Rostock</city>
        <zip>D-18147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reparto di Neurologia - Ospedale Misericordia</name>
      <address>
        <city>Grosseto</city>
        <zip>171 - 58100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit? di Napoli Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>5 - 80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unit? Operativa Parkinson e Disordini del Movimento</name>
      <address>
        <city>Pavia</city>
        <zip>6 - 27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Neuromed SRL Neurologia</name>
      <address>
        <city>Pozzilli</city>
        <zip>18 - 86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III Clinica Neurologica</name>
      <address>
        <city>Roma</city>
        <zip>30 - 00185</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Militzary Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Neurology</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology</name>
      <address>
        <city>Belrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>119 - 08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>25-29 08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <zip>25-27 - 08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <last_update_submitted>August 21, 2014</last_update_submitted>
  <last_update_submitted_qc>August 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <responsible_party>
    <name_title>Eisai Medical Services</name_title>
    <organization>Eisai Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

